课题基金 / 基金详情

Who Benefits from tPA 3-6 hours after Stroke

Who Benefits from tPA 3-6 hours after Stroke
中风后 3-6 小时谁可以从 tPA 中受益
批准号:
7034723
负责人:
MAARTEN G LANSBERG
金额:
$17.32万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-05-01 至 2011-04-30

项目摘要

项目成果

MAARTEN G LANSBERG的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Currently, the only FDA approved treatment for acute stroke is intravenous tissue plasminogen activator (iv tPA) administered within three hours after symptom onset. Only three percent of stroke patients in the United States receive iv tPA, because most patients present to the hospital beyond the three hour time-limit for iv tPA. Although clinical trials have not demonstrated benefit from iv tPA beyond three hours, a subgroup of stroke patients who benefit is likely to exist. This subgroup needs to be identified in order to increase the proportion of stroke patients who may be treated with tPA. The candidate proposes, in three Specific Aims, to investigate whether 1) clinical, 2) computed tomography (CT) and 3) magnetic resonance imaging (MRI) characteristics help identify patients who are most likely to have a favorable response to iv tPA in the three to six hour time-window. Based on the results of these projects, the candidate intents to develop a practical clinical prediction tool, which will enable physicians to stratify acute stroke patients and identify those who are most likely to have a favorable response to tPA. Dr. Lansberg is completing his Cerebrovascular Fellowship at Stanford University Medical Center and he will join the staff of the Department of Neurology and Neurological Sciences at Stanford University on July 1, 2004. His career goal is to improve the health of stroke patients through clinical research and direct patient care. His career development plan combines a highly relevant clinical research proposal with complementary didactic training. He will complete a Master of Science Program in Clinical Epidemiology and Biostatistics and he will get training in MRI technology. The candidate has a team of mentors who are world-renowned researchers in the following four fields: Clinical studies of acute stroke, neuroradiology, MRI physics and biostatistics. They will provide guidance throughout the award period and facilitate his transition into a successful independent investigator.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ARCADIA CSI (Cognition and Silent Infarcts)
  • 批准号:
    10207805
  • 项目类别:
  • 资助金额:
    $160.91万
  • 财政年份:
    2019
  • 负责人:
    MAARTEN G LANSBERG
  • 依托单位:
ARCADIA CSI (Cognition and Silent Infarcts)
  • 批准号:
    10450768
  • 项目类别:
  • 资助金额:
    $20.86万
  • 财政年份:
    2019
  • 负责人:
    MAARTEN G LANSBERG
  • 依托单位:
CTP to predict Response to recanalization in Ischemic Stroke Project (CRISP)
  • 批准号:
    8431810
  • 项目类别:
  • 资助金额:
    $56.13万
  • 财政年份:
    2011
  • 负责人:
    MAARTEN G LANSBERG
  • 依托单位:
CTP to predict Response to recanalization in Ischemic Stroke Project (CRISP)
  • 批准号:
    8246275
  • 项目类别:
  • 资助金额:
    $62.75万
  • 财政年份:
    2011
  • 负责人:
    MAARTEN G LANSBERG
  • 依托单位:
国内基金
海外基金
生物钟核受体Rev-erbα在缺血性卒中神经元能量代谢中的改善作用及机制研究
  • 批准号:
    82371332
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    胡琴
  • 依托单位:
内源性蛋白酶抑制剂SerpinA3N对缺血性脑卒中后血脑屏障的保护作用及其表达调控机制
  • 批准号:
    82371317
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    万杰清
  • 依托单位:
KLK10调控胶质—血管耦合与对话促缺血性卒中后血脑屏障修复的机制
  • 批准号:
    82371465
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    李龙宣
  • 依托单位:
基于仿生矿化法构建氢离子捕获的炎症调节性水凝胶微球在卒中治疗中的研究
  • 批准号:
    82372120
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    阮慧瞳
  • 依托单位: